Safety and efficacy of (+)‐epicatechin in subjects with Friedreich's ataxia: A phase II , open‐label, prospective study

Volume: 44, Issue: 2, Pages: 502 - 514
Published: Aug 31, 2020
Abstract
(+)-Epicatechin (EPI) induces mitochondrial biogenesis and antioxidant metabolism in muscle fibers and neurons. We aimed to evaluate safety and efficacy of (+)-EPI in pediatric subjects with Friedreich's ataxia (FRDA).This was a phase II, open-label, baseline-controlled single-center trial including 10 participants ages 10 to 22 with confirmed FA diagnosis. (+)-EPI was administered orally at 75 mg/d for 24 weeks, with escalation to 150 mg/d at...
Paper Details
Title
Safety and efficacy of (+)‐epicatechin in subjects with Friedreich's ataxia: A phase II , open‐label, prospective study
Published Date
Aug 31, 2020
Volume
44
Issue
2
Pages
502 - 514
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.